Literature DB >> 19556315

The development of patient-reported outcome indices for multiple sclerosis (PRIMUS).

L C Doward1, S P McKenna, D M Meads, J Twiss, B J Eckert.   

Abstract

BACKGROUND: Complex diseases such as multiple sclerosis (MS) present dilemmas over the choice of patient-reported outcome measures as no single scale can inform on all types of MS impact from the patient's perspective.
OBJECTIVE: To develop an outcome tool, the Patient-Reported Indices for Multiple Sclerosis (PRIMUS), to assess MS symptoms, activities, and quality of life.
METHODS: PRIMUS content was derived from qualitative interviews with UK MS patients and checked by clinical experts. Semi-structured cognitive debriefing interviews assessed scale face and content validity. PRIMUS scaling properties, reliability, and construct validity were assessed by a test-retest postal survey.
RESULTS: Cognitive debriefing interviews (n = 15) demonstrated scale clarity, relevance, and comprehensiveness. The postal survey was completed by 135 patients with MS. After removal of misfitting items and those exhibiting differential item functioning, all scales fitted the Rasch model, confirming unidimensionality. For all scales, test-retest reliability exceeded 0.80. Scale scores were related to perceived MS severity, general health, and symptoms of depression. Moderate correlations were observed between PRIMUS and Nottingham Health Profile scores.
CONCLUSIONS: Clinicians and researchers can have confidence in scores obtained by respondents on the PRIMUS. The PRIMUS will aid the assessment of the impact of MS from the patient's perspective.

Entities:  

Mesh:

Year:  2009        PMID: 19556315     DOI: 10.1177/1352458509106513

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  23 in total

Review 1.  Secondary Progressive Multiple Sclerosis: Definition and Measurement.

Authors:  Domenico Plantone; Floriana De Angelis; Anisha Doshi; Jeremy Chataway
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

Review 2.  Multiple sclerosis.

Authors:  Massimo Filippi; Amit Bar-Or; Fredrik Piehl; Paolo Preziosa; Alessandra Solari; Sandra Vukusic; Maria A Rocca
Journal:  Nat Rev Dis Primers       Date:  2018-11-08       Impact factor: 52.329

Review 3.  Quality of life in multiple sclerosis: determinants, measurement, and use in clinical practice.

Authors:  Deborah M Miller; Rebecca Allen
Journal:  Curr Neurol Neurosci Rep       Date:  2010-09       Impact factor: 5.081

4.  Combination treatment of fingolimod with antidepressants in relapsing-remitting multiple sclerosis patients with depression: a multicentre, open-label study - REGAIN.

Authors:  Antonios Bayas; Katrin Schuh; Monika Baier; Stefan Viktor Vormfelde
Journal:  Ther Adv Neurol Disord       Date:  2016-06-03       Impact factor: 6.570

Review 5.  Evolution of Patient-Reported Outcomes and Their Role in Multiple Sclerosis Clinical Trials.

Authors:  Cindy J Nowinski; Deborah M Miller; David Cella
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 6.  Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting.

Authors:  Carmen Tur; Marcello Moccia; Frederik Barkhof; Jeremy Chataway; Jaume Sastre-Garriga; Alan J Thompson; Olga Ciccarelli
Journal:  Nat Rev Neurol       Date:  2018-01-12       Impact factor: 42.937

7.  Assessing quality of life in Crohn's disease: development and validation of the Crohn's Life Impact Questionnaire (CLIQ).

Authors:  Jeanette Wilburn; Stephen P McKenna; James Twiss; Karen Kemp; Simon Campbell
Journal:  Qual Life Res       Date:  2015-02-22       Impact factor: 4.147

8.  Validation of a new quality of life scale related to multiple sclerosis and relapses.

Authors:  Antoine Baroin; Gilles Chopard; Gaye Siliman; Clément Michoudet; Aurore Vivot; Chrystelle Vidal; Hassna Mokadym; Annick Lavier; Eric Berger; Lucien Rumbach; Nathalie Rude
Journal:  Qual Life Res       Date:  2012-12-18       Impact factor: 4.147

9.  Comparing the impact of psoriasis and atopic dermatitis on quality of life: co-calibration of the PSORIQoL and QoLIAD.

Authors:  J Twiss; S P McKenna
Journal:  Qual Life Res       Date:  2014-01-30       Impact factor: 4.147

10.  Evaluation of an online platform for multiple sclerosis research: patient description, validation of severity scale, and exploration of BMI effects on disease course.

Authors:  Riley Bove; Elizabeth Secor; Brian C Healy; Alexander Musallam; Timothy Vaughan; Bonnie I Glanz; Emily Greeke; Howard L Weiner; Tanuja Chitnis; Paul Wicks; Philip L De Jager
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.